8-K: Neuronetics Reports Q1 2026 Results, Revenue Up 8%

Neuronetics announced its first quarter 2026 financial results, reporting an 8% increase in total revenue to $34.5 million, driven by strong U.S. clinic revenue growth.

Summary

• Neuronetics reported first quarter 2026 revenue of $34.5 million, an 8% increase year-over-year.
• U.S. clinic revenue grew 15% to $21.5 million.
• 34 NeuroStar systems were shipped in the U.S., a 10% increase compared to Q1 2025.
• Net cash used in operations was $9.4 million, a significant reduction from $17.0 million in Q1 2025.
• Gross margin decreased to 46.9% from 49.2% in the prior year's quarter, attributed to product mix.
• Operating expenses decreased by 6% to $25.1 million.
• The net loss for the quarter was $10.8 million, or $(0.16) per share, an improvement from a net loss of $12.7 million, or $(0.21) per share, in Q1 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with revenue growth and improved cash flow, but tempered by a decrease in gross margin and continued net losses.

Positives

• Total revenue increased by 8% to $34.5 million in Q1 2026.
• U.S. clinic revenue showed strong growth of 15% to $21.5 million.
• Shipments of NeuroStar systems increased by 10% to 34 units.
• Net cash used in operations significantly reduced by $7.6 million to $9.4 million.
• Operating expenses were reduced by 6% to $25.1 million.
• Net loss per share improved to $(0.16) from $(0.21) in the prior year.

Negatives

• Gross margin decreased to 46.9% from 49.2% due to product mix.
• U.S. treatment session revenue decreased by 5% to $9.1 million.
• International revenue decreased by 54% to $0.2 million.

Risks

• The company has a history of losses and may not achieve or sustain profitable operations.
• Reliance on the sale and usage of the NeuroStar Advanced Therapy System for revenues.
• Availability of coverage and reimbursement from third-party payors.
• Physician and patient demand for treatments.
• Developments in competing technologies and therapies.
• Potential effects of evolving and/or extensive government regulation.

Future Outlook

For the second quarter of 2026, the Company expects total revenue growth in the mid-single digits. For the full year 2026, Neuronetics continues to expect total revenue between $160 million and $166 million, gross margin between 47% and 49%, operating expenses between $100 million and $105 million, and cash flow from operations between negative $13 million and negative $17 million.

Management Comments

• I'm encouraged by our first quarter performance, which reflects the team's continued execution on revenue growth, operational efficiency, and cash management.
• Our clinic business delivered double-digit growth, we reduced operating expenses, and we meaningfully improved our operating cash flow versus the first quarter of last year.
• Looking ahead, I believe there is significant value in this business that has yet to be fully realized.
• We have the leading technology in TMS, a national clinic platform with real growth runway, and a team that is driving operational execution.
• Our team is focused on delivering better outcomes for our customers and patients, as well as long term value for our shareholders.

Industry Context

StockSavvy.ai notes that Neuronetics' Q1 2026 results show continued revenue growth in its core U.S. clinic business, aligning with broader trends in the medical technology sector focusing on specialized therapies for mental health conditions. The expansion of insurance coverage for TMS therapy, as indicated by Optum/UHC/UBH, is a positive development for the industry.

Comparison to Industry Standards

• The 8% year-over-year revenue growth for Neuronetics in Q1 2026 is a solid performance, though specific industry benchmarks for TMS providers are not detailed in the filing.
• The reduction in net cash used in operations is a positive step towards profitability, an area of focus for many companies in the medical device sector.
• The gross margin of 46.9% is within the projected range of 47%-49% for the full year, indicating management's ability to forecast within their expected parameters.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if profitability is achieved, but continued net losses present risk.
• Patients: Increased access to NeuroStar Advanced Therapy due to expanded insurance policies.
• Healthcare Providers: Expanded ability for Nurse Practitioners to order, supervise, and administer NeuroStar therapy.
• Employees: Continued focus on talent retention and operational execution.

Next Steps

• Continue execution on revenue growth, operational efficiency, and cash management.
• Focus on delivering better outcomes for customers and patients.
• Drive long-term value for shareholders.
• Expand SPRAVATO offering and explore potential for psychedelic therapies.
• Standardize operational excellence across the clinic network.

Key Dates

Recommendation

The company shows signs of operational improvement with revenue growth and reduced cash burn, but the continued net losses and declining gross margin warrant a cautious 'hold' rating. Investors should monitor progress towards profitability and the impact of strategic initiatives.

Keywords

Neuronetics, NeuroStar, TMS Therapy, Medical Technology, Financial Results, Q1 2026, Healthcare, Depression Treatment